Disorders of fatty acid metabolism: Pathology review

Last updated: November 01, 2022

Disorders of fatty acid metabolism: Pathology review

Step 1

Step 1

Tuberculosis: Pathology review
Obstructive lung diseases: Pathology review
Restrictive lung diseases: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Pneumonia: Pathology review
Respiratory distress syndrome: Pathology review
Cystic fibrosis: Pathology review
Disorders of sex chromosomes: Pathology review
Prostate disorders and cancer: Pathology review
Testicular tumors: Pathology review
Uterine disorders: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Benign breast conditions: Pathology review
Complications during pregnancy: Pathology review
Congenital TORCH infections: Pathology review
Breast cancer: Pathology review
Vaginal and vulvar disorders: Pathology review
Androgens and antiandrogens
Adrenergic antagonists: Alpha blockers
PDE5 inhibitors
Estrogens and antiestrogens
Uterine stimulants and relaxants
Aromatase inhibitors
Progestins and antiprogestins
Congenital renal disorders: Pathology review
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Osmotic diuretics
Loop diuretics
Potassium sparing diuretics
Carbonic anhydrase inhibitors
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Congenital neurological disorders: Pathology review
Headaches: Pathology review
Seizures: Pathology review
Cerebral vascular disease: Pathology review
Traumatic brain injury: Pathology review
Spinal cord disorders: Pathology review
Dementia: Pathology review
Central nervous system infections: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Adult brain tumors: Pathology review
Pediatric brain tumors: Pathology review
Neurocutaneous disorders: Pathology review
General anesthetics
Local anesthetics
Neuromuscular blockers
Back pain: Pathology review
Rheumatoid arthritis and osteoarthritis: Pathology review
Gout and pseudogout: Pathology review
Seronegative and septic arthritis: Pathology review
Systemic lupus erythematosus (SLE): Pathology review
Bone disorders: Pathology review
Bone tumors: Pathology review
Myalgias and myositis: Pathology review
Neuromuscular junction disorders: Pathology review
Pigmentation skin disorders: Pathology review
Acneiform skin disorders: Pathology review
Vesiculobullous and desquamating skin disorders: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Skin cancer: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Leukemias: Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Congenital gastrointestinal disorders: Pathology review
Esophageal disorders: Pathology review
Inflammatory bowel disease: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Malabsorption syndromes: Pathology review
Diverticular disease: Pathology review
Gastrointestinal bleeding: Pathology review
Appendicitis: Pathology review
Colorectal polyps and cancer: Pathology review
Pancreatitis: Pathology review
Jaundice: Pathology review
Viral hepatitis: Pathology review
Cirrhosis: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Vertigo: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Hypothyroidism: Pathology review
Hyperthyroidism: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Diabetes mellitus: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Multiple endocrine neoplasia: Pathology review
Diabetes insipidus and SIADH: Pathology review
Acyanotic congenital heart defects: Pathology review
Cyanotic congenital heart defects: Pathology review
Atherosclerosis and arteriosclerosis: Pathology review
Coronary artery disease: Pathology review
Peripheral artery disease: Pathology review
Valvular heart disease: Pathology review
Cardiomyopathies: Pathology review
Heart failure: Pathology review
Supraventricular arrhythmias: Pathology review
Aortic dissections and aneurysms: Pathology review
Pericardial disease: Pathology review
Endocarditis: Pathology review
Shock: Pathology review
Hypertension: Pathology review
Vasculitis: Pathology review
Cardiac and vascular tumors: Pathology review
Autosomal trisomies: Pathology review
Miscellaneous genetic disorders: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Disorders of carbohydrate metabolism: Pathology review
Disorders of fatty acid metabolism: Pathology review
Glycogen storage disorders: Pathology review
Dyslipidemias: Pathology review
Lysosomal storage disorders: Pathology review
Fat-soluble vitamin deficiency and toxicity: Pathology review

Transcript

Watch video only

Two kids are brought to the clinic by their mothers. The first one’s Dalia, a 2 year old girl. Her mother is concerned because Dalia always seems to be tired and weak, and in general doesn’t eat much. On physical examination of the abdomen, you palpate an enlarged liver. You decide to run a blood test, which reveals that her blood glucose and ketone bodies are decreased, but what really stands out to you is that her carnitine levels are also really low.

After Dalia, you see Luca, a 3 year old boy who had a brief seizure earlier that day. Luca’s mother tells you that he’s had gastroenteritis for the past few days, so he’s been vomiting and not eating much. You decide to run a blood test, which also reveals low blood glucose and ketone bodies, but unlike Dalia, he has high levels of fatty acyl-carnitine.

Based on the initial presentation, both Dalia and Luca seem to have some fatty acid metabolism disorder. Now, let’s review fatty acid metabolism real quick. Normally, the body's main source of energy is the glucose we get from food. When glucose is running low, like with prolonged fasting or exercise, the body is able to obtain energy from stored fats.

The simplest form of fats are fatty acids, which are grouped by length into short, medium, long, and very long chain fatty acids. Short and medium chain fatty acids are primarily obtained from the diet, while long and very long chain fatty acids can be synthesized from acetyl-CoA by the liver and fat cells.

Now, keep in mind that acetyl-CoA is usually found in the mitochondrial matrix, whereas the enzymes required for fatty acid synthesis are all in the cytoplasm. For acetyl-CoA to cross the mitochondrial membranes and get to the cytoplasm, it first needs to combine with oxaloacetate to form citrate. Once in the cytoplasm, an enzyme called citrate lyase leaves citrate back into acetyl-CoA and oxaloacetate. This whole process is called the citrate shuttle.

Now, when the body needs some extra energy, fatty acids can be broken down by the acyl-CoA dehydrogenases into smaller chain fatty acids to ultimately obtain acetyl-CoA. This process is called fatty acid or beta oxidation. To do this, fatty acids need to leave the fat cells, and enter the bloodstream, where they bind to a protein called albumin.

Albumin carries the fatty acids to the heart, skeletal muscle, and liver cells, which is where fatty acid oxidation mainly takes place. Once inside these cells, a cytosolic enzyme called fatty acyl-CoA synthetase adds a coenzyme A or CoA molecule to the end of the fatty acid, turning it into a fatty acyl-CoA.

Now, oxidation of very long chain fatty acyl-CoAs takes place in the peroxisomes, and that’s another topic; on the other hand, oxidation of short, medium, and long chain fatty acyl-CoAs takes place in the mitochondrial matrix. What’s important here is that short and medium chain fatty acyl-coAs can freely cross the mitochondrial membranes, while the long chain fatty acyl-CoAs can’t.

To get around this problem, an enzyme within the outer mitochondrial membrane called carnitine palmitoyltransferase 1 or CPT1 replaces the CoA with a carnitine, making fatty acyl-carnitine and a free CoA, both of which can easily cross the inner mitochondrial membrane. Then, along the inner mitochondrial membrane, another enzyme called carnitine palmitoyltransferase 2 or CPT2 substitutes carnitine and CoA back, therefore regenerating fatty acyl-CoA and free carnitine within the mitochondrial matrix. This whole process is called the carnitine shuttle, and it’s very high yield.

With prolonged starvation, fatty acid oxidation ramps up, and the excess acetyl-CoA is sent to the liver to get converted into ketone bodies. These ketone bodies are then released into the bloodstream, so that they can reach the rest of the body and be used to obtain energy.

Now, fatty acid metabolism disorders result from a defect of an enzyme involved in obtaining energy sources like acetyl-CoA and ketone bodies from fatty acids. For your exams, the two most high yield fatty acid metabolism disorders are systemic carnitine deficiency and medium chain acyl-CoA dehydrogenase deficiency.

Let’s begin with systemic carnitine deficiency, in which there’s not enough carnitine available to assist in the carnitine shuttle. Systemic carnitine deficiency can be primary or secondary. Systemic primary carnitine deficiency, or SPCD for short, is caused by a mutation in the SLC22A5 gene, which codes for the organic cation transporter protein OCTN2.

For your exams, remember that this is an autosomal recessive disease, meaning that an individual needs to inherit two copies of the mutated gene, one from each parent, to develop the condition. Now, OCTN2 is a carnitine transporter that would normally help reabsorb carnitine in kidneys, as well as transport carnitine inside cells capable of fatty acid oxidation.

As a result, in primary carnitine deficiency, most of the carnitine ends up being excreted in urine, leading to a carnitine shortage in the body. And even that little carnitine available can’t be transported inside the cells to be used in the carnitine shuttle. As a result, long chain fatty acids can’t get into the mitochondria, so fatty acid oxidation is impaired.

Systemic primary carnitine deficiency often first manifests in infants or young children as fatigue and weakness. In addition, the child may show irritability and feeding difficulties. What’s most important for your exams is that, during fasting, individuals may experience hypoketotic hypoglycemia, which is basically an episode of low blood sugar that can’t be compensated by producing ketone bodies to obtain energy.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management" Pediatric Research (2005)
  6. "A Fetal Fatty-Acid Oxidation Disorder as a Cause of Liver Disease in Pregnant Women" New England Journal of Medicine (1999)